Intraoperative Tumor Detection Using Pafolacianine

Abstract

Cancer is a leading cause of death worldwide, with increasing numbers of new cases each year. For the vast majority of cancer patients, surgery is the most effective procedure for the complete removal of the malignant tissue. However, relapse due to the incomplete resection of the tumor occurs very often, as the surgeon must rely primarily on visual and tactile feedback. Intraoperative near-infrared imaging with pafolacianine is a newly developed technology designed for cancer detection during surgery, which has been proven to show excellent results in terms of safety and efficacy. Therefore, pafolacianine was approved by the U.S. Food and Drug Administration (FDA) on 29 November 2021, as an additional approach that can be used to identify malignant lesions and to ensure the total resection of the tumors in ovarian cancer patients. Currently, various studies have demonstrated the positive effects of pafolacianine’s use in a wide variety of other malignancies, with promising results expected in further research. This review focuses on the applications of the FDA-approved pafolacianine for the accurate intraoperative detection of malignant tissues. The cancer-targeting fluorescent ligands can shift the paradigm of surgical oncology by enabling the visualization of cancer lesions that are difficult to detect by inspection or palpation. The enhanced detection and removal of hard-to-detect cancer tissues during surgery will lead to remarkable outcomes for cancer patients and society, specifically by decreasing the cancer relapse rate, increasing the life expectancy and quality of life, and decreasing future rates of hospitalization, interventions, and costs.

Indocyanine-Green-Loaded Liposomes for Photodynamic and Photothermal Therapies: Inducing Apoptosis and Ferroptosis in Cancer Cells with Implications beyond Oral Cancer

“…Investigating whether Lipo-ICGs demonstrate a ferroptotic effect during sonographic stimulation would be an intriguing line of inquiry. In addition, the Food and Drug Administration (FDA) has approved certain cancer-detecting pharmaceuticals derived from ICG, such as Pafolacianine [ 33 ]. This compound, a fusion of a folate analog and ICG, exhibits promising targeting capabilities for cancers rich in folate receptors.…”

Subsurface fluorescence time-of-flight imaging using a large-format single-photon avalanche diode sensor for tumor depth assessment

“…The coefficient c fluo from Eqs. (10) and (11) is in theory constant and only depends on the setup geometry.…”

Comparative aspects of targeted sentinel lymph node mapping in veterinary and human medicine: opportunities for future research

“…Despite its high rate of false positives, OTL38 has potential use for selective SLN mapping based on factors such as cancer stage and histological subtypes that could have different lymph node metastatic rates ( 69 ). Limitations of OTL38 were noted in image interpretation errors and false positives and negatives, specifically in non-malignant regional lymph nodes ( 70 ).…”